Covered recipient · General Payments record
MICHAEL W SCHUSTER
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$167,919.39
183 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $117,752.00 | 40 |
| Travel and Lodging | $30,429.90 | 68 |
| Consulting Fee | $8,089.50 | 6 |
| Honoraria | $6,960.00 | 2 |
| Food and Beverage | $4,687.99 | 67 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $34,774.31 | 40 |
| Janssen Biotech, Inc. | $31,045.94 | 51 |
| Astellas Pharma US Inc | $21,794.55 | 13 |
| E.R. Squibb & Sons, L.L.C. | $18,945.76 | 14 |
| Incyte Corporation | $12,874.34 | 12 |
| Amgen Inc. | $11,240.41 | 10 |
| Karyopharm Therapeutics Inc. | $9,372.91 | 6 |
| BeiGene USA, Inc. | $8,775.00 | 4 |
| ABBVIE INC. | $8,371.07 | 6 |
| SOBI, INC | $3,237.50 | 2 |
| Novartis Pharmaceuticals Corporation | $3,209.51 | 3 |
| Regeneron Pharmaceuticals, Inc. | $2,469.51 | 5 |
| GENZYME CORPORATION | $831.00 | 1 |
| Celgene Corporation | $619.82 | 3 |
| Rigel Pharmaceuticals, Inc. | $57.82 | 2 |
| Daiichi Sankyo Inc. | $51.57 | 2 |
| BioLineRx USA, Inc. | $41.18 | 1 |
| SANOFI-AVENTIS U.S. LLC | $38.66 | 1 |
| Azurity Pharmaceuticals, Inc. | $35.94 | 1 |
| AstraZeneca Pharmaceuticals LP | $35.00 | 1 |
| GlaxoSmithKline, LLC. | $33.06 | 2 |
| PharmaEssentia USA Corporation | $26.65 | 1 |
| Agios Pharmaceuticals, Inc. | $23.53 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.35 | 1 |
Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MICHAEL W SCHUSTER
NPI 1669569752 · CMS profile ID 29919
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
NEW YORK, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1669569752?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MICHAEL W SCHUSTER, NPI 1669569752, CMS profile ID 29919. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669569752?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MICHAEL W SCHUSTER, NPI 1669569752, CMS profile ID 29919. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669569752?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MICHAEL W SCHUSTER, NPI 1669569752, CMS profile ID 29919, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1669569752?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
183 matching records · $167,919.39 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 183.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $184.37 | 05/29/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131737394 | CMS |
| PFIZER INC. | $4,250.00 | 05/28/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131737396 | CMS |
| PFIZER INC. | $125.00 | 05/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131737410 | CMS |
| PFIZER INC. | $25.46 | 05/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131810173 | CMS |
| PFIZER INC. | $241.89 | 05/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131811840 | CMS |
| PFIZER INC. | $3,275.00 | 05/20/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131810175 | CMS |
| PFIZER INC. | $111.79 | 05/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131815422 | CMS |
| Astellas Pharma US Inc | $122.16 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139379770 | CMS |
| Astellas Pharma US Inc | $1,830.44 | 05/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139387540 | CMS |
| Astellas Pharma US Inc | $263.44 | 05/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139387542 | CMS |
| Astellas Pharma US Inc | $5,100.00 | 05/09/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139387544 | CMS |
| Incyte Corporation | $4,110.00 | 05/07/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141195405 | CMS |
| Daiichi Sankyo Inc. | $29.08 | 05/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089479811 | CMS |
| E.R. Squibb & Sons, L.L.C. | $103.88 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101323248 | CMS |
| E.R. Squibb & Sons, L.L.C. | $167.83 | 05/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101323250 | CMS |
| Incyte Corporation | $342.50 | 05/01/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141287530 | CMS |
| Incyte Corporation | $23.67 | 04/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141281182 | CMS |
| Incyte Corporation | $209.04 | 04/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141213374 | CMS |
| Incyte Corporation | $323.58 | 04/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141213390 | CMS |
| Incyte Corporation | $123.06 | 04/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141242370 | CMS |
| Incyte Corporation | $53.02 | 04/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141289836 | CMS |
| Janssen Biotech, Inc. | $4,125.00 | 04/03/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078441214 | CMS |
| Incyte Corporation | $4,110.00 | 04/02/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141208423 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.35 | 03/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144966863 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3,176.00 | 03/27/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101323236 | CMS |
| Incyte Corporation | $29.48 | 03/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141255648 | CMS |
| Incyte Corporation | $124.99 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141315597 | CMS |
| Janssen Biotech, Inc. | $26.70 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078440801 | CMS |
| Janssen Biotech, Inc. | $115.31 | 03/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078444322 | CMS |
| SOBI, INC | $1,850.00 | 03/22/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141417708 | CMS |
| Astellas Pharma US Inc | $125.00 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139379766 | CMS |
| Astellas Pharma US Inc | $4,820.00 | 03/20/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139387546 | CMS |
| Astellas Pharma US Inc | $676.54 | 03/20/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139387548 | CMS |
| Janssen Biotech, Inc. | $4,125.00 | 03/20/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078440833 | CMS |
| Janssen Biotech, Inc. | $628.17 | 03/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078454453 | CMS |
| Janssen Biotech, Inc. | $60.00 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078439829 | CMS |
| Janssen Biotech, Inc. | $79.96 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078440969 | CMS |
| Janssen Biotech, Inc. | $39.99 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078445785 | CMS |
| Janssen Biotech, Inc. | $39.99 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078445849 | CMS |
| Janssen Biotech, Inc. | $60.00 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078447878 | CMS |
| Janssen Biotech, Inc. | $39.99 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078448599 | CMS |
| Janssen Biotech, Inc. | $79.96 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078451027 | CMS |
| Janssen Biotech, Inc. | $39.99 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078453828 | CMS |
| Janssen Biotech, Inc. | $79.96 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078454457 | CMS |
| Janssen Biotech, Inc. | $60.00 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078457976 | CMS |
| Janssen Biotech, Inc. | $60.00 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078458209 | CMS |
| Janssen Biotech, Inc. | $79.96 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078458622 | CMS |
| Janssen Biotech, Inc. | $147.62 | 03/15/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078441139 | CMS |
| Janssen Biotech, Inc. | $150.00 | 03/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078441513 | CMS |
| Janssen Biotech, Inc. | $150.00 | 03/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078442242 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,672.47 | 11 |
| PY2025 | Principal investigator | $1,029,265.41 | 203 |
| PY2024 | Principal investigator | $285,981.04 | 71 |
| PY2023 | Principal investigator | $184,796.16 | 87 |
| PY2022 | Recipient | $780.00 | 1 |
| PY2022 | Principal investigator | $38,774.14 | 13 |
| PY2021 | Recipient | $4,600.00 | 2 |
| PY2021 | Principal investigator | $42,907.79 | 22 |
| PY2020 | Recipient | $1,270.00 | 2 |
| PY2020 | Principal investigator | $97,848.17 | 25 |
| PY2019 | Principal investigator | $264,201.51 | 60 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
214 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,438.10 | 12/22/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184279514 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,438.10 | 12/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184278340 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $357.30 | 12/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184278342 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $357.30 | 12/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184278344 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,952.20 | 12/19/2025 | Non-covered Recipient Entity THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184278800 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276962 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $694.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276964 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276966 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276968 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276970 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276972 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276974 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276976 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276978 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276980 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276982 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276984 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276986 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 12/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184276988 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,225.10 | 12/11/2025 | Non-covered Recipient Entity THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184274256 |
| Principal investigator 1 | Incyte Corporation | $4,332.00 | 12/10/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596914 |
| Principal investigator 1 | Incyte Corporation | $2,192.00 | 12/10/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596917 |
| Principal investigator 1 | Incyte Corporation | $2,961.00 | 12/10/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596934 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,259.44 | 12/07/2025 | Covered Recipient Physician | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122261 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $279.85 | 12/05/2025 | Covered Recipient Physician | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122249 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $309.06 | 12/05/2025 | Covered Recipient Physician | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122251 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $78.97 | 12/05/2025 | Covered Recipient Physician | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122253 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $33.55 | 12/05/2025 | Covered Recipient Physician | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122255 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $59.56 | 12/05/2025 | Covered Recipient Physician | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122257 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $19.26 | 12/05/2025 | Covered Recipient Physician | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122259 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 12/05/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184269637 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.00 | 12/05/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184269639 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.00 | 12/05/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184269641 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 12/05/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184269643 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.00 | 12/05/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184269645 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 12/05/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184269647 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 12/05/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184269649 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,438.10 | 11/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184265821 |
| Principal investigator 1 | Incyte Corporation | $2,285.40 | 11/21/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596905 |
| Principal investigator 1 | Incyte Corporation | $3,071.00 | 11/21/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596922 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $455.00 | 11/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184262197 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,820.00 | 11/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184262199 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,306.90 | 11/14/2025 | Non-covered Recipient Entity THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184261085 |
| Principal investigator 1 | Incyte Corporation | $4,024.00 | 11/12/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596902 |
| Principal investigator 1 | Incyte Corporation | $4,698.00 | 11/12/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596910 |
| Principal investigator 1 | Incyte Corporation | $4,020.00 | 11/12/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596925 |
| Principal investigator 1 | Incyte Corporation | $2,479.00 | 11/12/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596930 |
| Principal investigator 1 | Incyte Corporation | $161.80 | 11/10/2025 | Non-covered Recipient Entity STONY BROOK UNIVERSITY MEDICAL CENTER | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240597204 |
| Principal investigator 1 | Incyte Corporation | $114.50 | 11/10/2025 | Non-covered Recipient Entity STONY BROOK UNIVERSITY MEDICAL CENTER | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240597209 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,900.80 | 11/06/2025 | Non-covered Recipient Entity THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184257727 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,030.00 | 10/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184253366 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,030.00 | 10/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184253368 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,060.00 | 10/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184253370 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,030.00 | 10/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184253372 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,030.00 | 10/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184253374 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $319.01 | 10/16/2025 | Covered Recipient Physician | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122247 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,008.60 | 10/13/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184249929 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,008.60 | 10/13/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184249931 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25,223.90 | 10/09/2025 | Non-covered Recipient Entity THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184248850 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $390.92 | 10/03/2025 | Covered Recipient Physician | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122245 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,811.60 | 10/03/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184245825 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,819.10 | 10/01/2025 | Non-covered Recipient Entity THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184244451 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $799.20 | 09/29/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184243887 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,513.80 | 09/29/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184243889 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 09/24/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184242285 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,483.00 | 09/24/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184242287 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 09/24/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184242289 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,483.00 | 09/24/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184242291 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 09/24/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184242293 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 09/24/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184242295 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 09/24/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184242297 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 09/24/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184242299 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 09/24/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184242301 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $347.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240892 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240894 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240896 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240898 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240900 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $242.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240902 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240904 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240906 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240908 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240910 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240912 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,041.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240914 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $242.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240916 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 09/19/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184240918 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,851.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238410 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $423.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238412 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $423.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238414 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,851.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238416 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,820.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238418 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $423.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238420 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,851.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238422 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $455.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238424 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,851.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238426 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $423.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238428 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $658.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238430 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $658.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238432 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $658.00 | 09/17/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184238434 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,827.90 | 08/28/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184231289 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,513.80 | 08/28/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184231291 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,513.80 | 08/28/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184231293 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,732.40 | 08/28/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184231295 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,513.80 | 08/28/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184231363 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 08/21/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184229523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $335.40 | 08/21/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184229525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 08/21/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184229527 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $177.00 | 08/21/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184229529 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,176.70 | 08/21/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184229533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,176.70 | 08/21/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184229535 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,176.70 | 08/21/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184229543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,176.70 | 08/21/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184229545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,176.70 | 08/21/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184229547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,810.00 | 08/21/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184229551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,810.00 | 08/21/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184229553 |
| Principal investigator 1 | Incyte Corporation | $2,300.00 | 08/20/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596870 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 08/20/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596874 |
| Principal investigator 1 | Incyte Corporation | $780.00 | 08/20/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596877 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 08/20/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596882 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 08/20/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596885 |
| Principal investigator 1 | Incyte Corporation | $10,000.00 | 08/20/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596889 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 08/20/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596893 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 08/20/2025 | Non-covered Recipient Entity STATE UNIVERSITY OF NEW YORK | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240596897 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 08/08/2025 | Non-covered Recipient Entity STONY BROOK UNIVERSITY MEDICAL CENTER | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240597220 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 08/08/2025 | Non-covered Recipient Entity STONY BROOK UNIVERSITY MEDICAL CENTER | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240597227 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,438.10 | 07/30/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184221900 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 07/09/2025 | Non-covered Recipient Entity STONY BROOK UNIVERSITY MEDICAL CENTER | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240597213 |
| Principal investigator 1 | Incyte Corporation | $29.39 | 07/09/2025 | Non-covered Recipient Entity STONY BROOK UNIVERSITY MEDICAL CENTER | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240597217 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 07/09/2025 | Non-covered Recipient Entity STONY BROOK UNIVERSITY MEDICAL CENTER | A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | No dispute reported | 06/30/2026 | 1240597225 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,810.00 | 06/30/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184212233 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,810.00 | 06/30/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184212235 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210918 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210920 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210922 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210924 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210926 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210928 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210930 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210932 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210934 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210936 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210938 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210940 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210942 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210944 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,672.40 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210946 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,176.70 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210948 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,176.70 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210950 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,176.70 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210952 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,176.70 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210954 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,176.70 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210956 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,176.70 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210958 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25,344.80 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210960 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25,344.80 | 06/25/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184210962 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,827.90 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208631 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,438.10 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,493.00 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208677 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,493.00 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208679 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,732.40 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208695 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,811.60 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208701 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,448.80 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208771 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,448.80 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208773 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,822.30 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208787 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,435.20 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208799 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,515.30 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208807 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,918.50 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208809 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,212.80 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208811 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,292.00 | 06/18/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184208813 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 06/02/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184200873 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 06/02/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184200875 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $72,540.00 | 06/02/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184202907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,083.40 | 04/23/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184186937 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 04/10/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184182882 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 04/10/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184182884 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $975.00 | 04/10/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184182886 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $975.00 | 04/10/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184182888 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $975.00 | 04/10/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184182890 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 04/10/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184182892 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 04/10/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184182894 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $975.00 | 04/10/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184182896 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,493.00 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156074 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,212.80 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156076 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,141.80 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156078 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,493.00 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156080 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,292.00 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156082 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,132.00 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156084 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,292.00 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156086 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,918.50 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156088 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,212.80 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156090 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,493.00 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156092 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,355.30 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156094 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,515.30 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156096 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,355.30 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156098 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,355.30 | 02/27/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) | No dispute reported | 06/30/2026 | 1184156100 |
| Recipient | GlaxoSmithKline, LLC. | $31.02 | 02/25/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI | No dispute reported | 06/30/2026 | 1192165211 |
| Recipient | GlaxoSmithKline, LLC. | $891.83 | 02/25/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI | No dispute reported | 06/30/2026 | 1192165215 |
| Principal investigator 1 | Celgene Corporation | $10,000.00 | 02/20/2025 | Non-covered Recipient Entity Research Foundation Of Suny | A Study to Evaluate the Efficacy and Safety of Lisocabtagene Maraleucel Monotherapy Compared to Investigators Choice Options (Idelalisib + Rituximab or Bendamustine + Rituximab) in Adult Participants with Double Class Exposed Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | No dispute reported | 06/30/2026 | 1222304939 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,775.50 | 02/12/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153660 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,874.60 | 02/12/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153662 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,874.60 | 02/12/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153664 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,874.60 | 02/12/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153666 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,874.60 | 02/12/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153668 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,874.60 | 02/12/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153670 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,775.50 | 02/12/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153672 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,874.60 | 02/12/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153674 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,093.00 | 01/08/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184146410 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,000.00 | 01/08/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184146412 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $780.00 | 01/08/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184146414 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,300.00 | 01/08/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184146416 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,500.00 | 01/08/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184146418 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,000.00 | 01/08/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184146420 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,496.00 | 01/08/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184146422 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,570.00 | 01/08/2025 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184146424 |